Navigation Links
Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
Date:6/16/2010

2009 and reports on Form 10-Q for the quarter ended March 31, 2010. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

Abbott Forward Looking Statement

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2009, and in Item 1A, "Risk Factors," to our Quarterly Report on Securities and Exchange Commission Form 10-Q for the period ended March 31, 2010, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
2. Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramals Healthcare Solutions Business
3. Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
4. Updated Abbott Statement: To Help Respond to Growing Health Crisis, Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts
5. Abbott Hosts Conference Call for Third-Quarter Earnings
6. Abbott Declares 343rd Consecutive Quarterly Dividend
7. Abbott Wins Top Honor in Wall Street Journal Technology Innovation Awards
8. Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
9. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
10. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
11. Abbott HIV Test Demonstrates Earlier Disease Detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... LONDON , August 3, 2015 ... Portland Hospital waved the shortfall of ... fanatic could stand normally for the first time. ...      (Photo: http://photos.prnewswire.com/prnh/20150803/254229 ) The ... Jude,s legs allowing him to carry out his wish ...
(Date:8/3/2015)... SAN DIEGO , Aug. 3, 2015  Aethlon Medical, ... affinity biofiltration devices to treat life-threatening diseases, today announced ... investor conference call and webcast on Thursday, August 13, ... call and webcast will follow the release of fiscal ... call will be available approximately two hours after the ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech Corporation introduces the ... line of analytical laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, ... resistant and maintenance-free solution for a broad range of vacuum filtration applications. , ...
(Date:7/30/2015)... Marshall, MN (PRWEB) , ... July 31, 2015 , ... ... Ralco Enrichment Center at the Lyon County Fair to be held August 5-9 in ... more about where their meals come from and how agriculture impacts their daily lives. ...
Breaking Biology Technology:Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Sterlitech Launches New Line of Vacuum Pumps 2Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... ... Doren, PharmD, will present at the 9th DIA Conference for Contemporary Pharmacovigilance and Risk Management ... present on the topic of the Integrated Summary of Safety. , ... Emeryville, CA (PRWEB) November 18, 2009 -- BioSoteria, Inc., ...
... , ... Medical Centers Simplify Clinical Workflow Using iSirona Technology , ... Panama City, Fla. (PRWEB) November ... today announced the successful "go-live" of iSirona,s DeviceConX at University Hospitals Geneva Medical ...
... activity in the brain. Even the mere possibility of receiving ... brain called the striatum. A team of Japanese researchers report ... , published by Elsevier, the results of a study in ... task and found high-risk/high-gain options to cause higher levels of ...
Cached Biology Technology:BioSoteria CEO to Present at Drug Safety Conference 2iSirona Announces Go-live at University Hospitals in Cleveland 2iSirona Announces Go-live at University Hospitals in Cleveland 3Monetary gain and high-risk tactics stimulate activity in the brain 2
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... second quarter ended June 30, 2015.  Revenue ... decrease of 33% compared to $6.8 million in the same ... 2015 was $0.3 million, or $0.01 per diluted share, which ... the same period a year ago.  Lower ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... Disorder , (#1119044, Wednesday, October 26, 3:00 PM Eastern) , ... vary in intensity, may be an indicator of periodic limb ... PMLD, researchers from Toledo, Ohio divided the patients into those ... 84 right-handed and 16 left-handed patients, 69% of right-handed patients ...
... PA, October 24, 2011 Nutrition Facts labels have ... these labels read in detail by consumers when making ... labels? According to a new study published in the ... Dietetic Association, consumers, self-reported viewing of Nutrition Facts ...
... for Science and Technology is the first post-secondary school to ... Experiments . Though JoVE , the first and ... video articles showing basic experimental procedures, the majority of the ... -- not the level of research one would usually associate ...
Cached Biology News:CHEST 2011: Embargoed studies highlight new sleep disorder research 2CHEST 2011: Embargoed studies highlight new sleep disorder research 3Consumers don't pay as much attention to nutrition fact labels as they think 2Consumers don't pay as much attention to nutrition fact labels as they think 3
Polyclonal Antibody to SHPRH...
Purified anti-PI3K p110 delta...
... Antigen Afinity Purified Tyrosine Hydroxylase ... antibody was raised against synthetic ... residues surrounding the phospho-Ser40 of ... antibody was purified by sequential ...
NF kappa B Related Sampler Kit 10g each...
Biology Products: